Risk factors for the development of endometrial lesions in breast cancer patients using tamoxyphen: a retrospective cohort study
breast cancer is the cancer with the highest incidence in women in Brazil, representing 29.7% of all cancers. More than two thirds of women with breast cancer show expression for hormone receptors, and in these cases, hormone therapy with tamoxifen is indicated, which may represent a risk factor for...
Gespeichert in:
| Veröffentlicht in: | Revista do Colegio Brasileiro de Cirurgioes 2023, Vol.50, p.e20233442 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | e20233442 |
| container_title | Revista do Colegio Brasileiro de Cirurgioes |
| container_volume | 50 |
| creator | Vizzotto, Jr, Alvo Orlando Nicolau, Sergio Mancini Lopes, Guilherme Munhoz Castelo Filho, Adauto |
| description | breast cancer is the cancer with the highest incidence in women in Brazil, representing 29.7% of all cancers. More than two thirds of women with breast cancer show expression for hormone receptors, and in these cases, hormone therapy with tamoxifen is indicated, which may represent a risk factor for the development of endometrial cancer (four-fold greater relative risk).
this study aimed to evaluate the association of tamoxifen and the development of endometrial disturbances and to assess possible other associated risk factors.
a total of 364 breast cancer patients were evaluated, 286 who used tamoxifen and 78 who did not use this hormone therapy. Results: patients who used tamoxifen had a mean follow-up time of 51.42 months similar to those without hormone therapy (p=0.081). A total of 21 (7.3%) women who used tamofixen and no cases among women without hormone therapy presented endometrial changes during follow-up (p=0.01). Despite information regarding obesity was available for only 270 women, obesity was also significantly associated with the development of endometrial changes (p=0.008).
furthermore, the association between tamofixen and endometrial changes remained significant (p=0.039) after adjusting for obesity. |
| doi_str_mv | 10.1590/0100-6991e-20233442-en |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_doaj_</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10595044</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_858dab7d980843428a2087989dcdbdfc</doaj_id><sourcerecordid>36995835</sourcerecordid><originalsourceid>FETCH-LOGICAL-c435n-94fbdfe58f2790902a5cfa188f5a87e0ad7d4eda3828aa5372c1613c15e2ac163</originalsourceid><addsrcrecordid>eNpVkd9uFCEUh4nR2LX6Cg0vMAoD7IA3xjT-adLExOg1OQtndqkzMAF249756NKu3dgryOH8vgN8hFxx9pYrw94xzli3NoZj17NeCCn7DuMzsuKamU4quX5OVuemC_KqlDvGpOBGvCQXohWVFmpF_nwP5RcdwdWUCx1TpnWH1OMBp7TMGCtNI8Xo04w1B5johCWkWGiIdJMRSqUOosNMF6ih9Re6LyFuaYU5_T4uO4zvKdDc0qks6Go4IHVpl3Klpe798TV5McJU8M2_9ZL8_Pzpx_XX7vbbl5vrj7edk0LFzshx40dUeuwHwwzrQbkRuNajAj0gAz94iR6E7jWAEkPv-JoLxxX20LbiktycuD7BnV1ymCEfbYJgHwopby3kGtyEVivtYTN4o5mWQjZgz_RgtPHOt0u4xvpwYi37zYzetWdnmJ5An57EsLPbdLCcKaOYlI2wPhFc-5aScTyHObP3gu29O_sg2D4Kthhb8Or_0efYo1HxF7tUpws</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Risk factors for the development of endometrial lesions in breast cancer patients using tamoxyphen: a retrospective cohort study</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>PubMed Central Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Vizzotto, Jr, Alvo Orlando ; Nicolau, Sergio Mancini ; Lopes, Guilherme Munhoz ; Castelo Filho, Adauto</creator><creatorcontrib>Vizzotto, Jr, Alvo Orlando ; Nicolau, Sergio Mancini ; Lopes, Guilherme Munhoz ; Castelo Filho, Adauto</creatorcontrib><description>breast cancer is the cancer with the highest incidence in women in Brazil, representing 29.7% of all cancers. More than two thirds of women with breast cancer show expression for hormone receptors, and in these cases, hormone therapy with tamoxifen is indicated, which may represent a risk factor for the development of endometrial cancer (four-fold greater relative risk).
this study aimed to evaluate the association of tamoxifen and the development of endometrial disturbances and to assess possible other associated risk factors.
a total of 364 breast cancer patients were evaluated, 286 who used tamoxifen and 78 who did not use this hormone therapy. Results: patients who used tamoxifen had a mean follow-up time of 51.42 months similar to those without hormone therapy (p=0.081). A total of 21 (7.3%) women who used tamofixen and no cases among women without hormone therapy presented endometrial changes during follow-up (p=0.01). Despite information regarding obesity was available for only 270 women, obesity was also significantly associated with the development of endometrial changes (p=0.008).
furthermore, the association between tamofixen and endometrial changes remained significant (p=0.039) after adjusting for obesity.</description><identifier>ISSN: 0100-6991</identifier><identifier>EISSN: 1809-4546</identifier><identifier>DOI: 10.1590/0100-6991e-20233442-en</identifier><identifier>PMID: 36995835</identifier><language>eng</language><publisher>Brazil: Colégio Brasileiro de Cirurgiões</publisher><subject>Breast Neoplasms ; Breast Neoplasms - pathology ; Endometrial Neoplasms - chemically induced ; Endometrial Neoplasms - epidemiology ; Female ; Hormones ; Humans ; Obesity ; Obesity - complications ; Original ; Retrospective Studies ; Risk Factors ; Tamoxifen ; Tamoxifen - adverse effects ; Uterine Diseases</subject><ispartof>Revista do Colegio Brasileiro de Cirurgioes, 2023, Vol.50, p.e20233442</ispartof><rights>2023 Revista do Colégio Brasileiro de Cirurgiões 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c435n-94fbdfe58f2790902a5cfa188f5a87e0ad7d4eda3828aa5372c1613c15e2ac163</citedby><cites>FETCH-LOGICAL-c435n-94fbdfe58f2790902a5cfa188f5a87e0ad7d4eda3828aa5372c1613c15e2ac163</cites><orcidid>0000-0001-6745-6502 ; 0000-0002-0290-6143 ; 0000-0003-3682-8443 ; 0000-0003-3767-7616</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10595044/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10595044/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,4024,27923,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36995835$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Vizzotto, Jr, Alvo Orlando</creatorcontrib><creatorcontrib>Nicolau, Sergio Mancini</creatorcontrib><creatorcontrib>Lopes, Guilherme Munhoz</creatorcontrib><creatorcontrib>Castelo Filho, Adauto</creatorcontrib><title>Risk factors for the development of endometrial lesions in breast cancer patients using tamoxyphen: a retrospective cohort study</title><title>Revista do Colegio Brasileiro de Cirurgioes</title><addtitle>Rev Col Bras Cir</addtitle><description>breast cancer is the cancer with the highest incidence in women in Brazil, representing 29.7% of all cancers. More than two thirds of women with breast cancer show expression for hormone receptors, and in these cases, hormone therapy with tamoxifen is indicated, which may represent a risk factor for the development of endometrial cancer (four-fold greater relative risk).
this study aimed to evaluate the association of tamoxifen and the development of endometrial disturbances and to assess possible other associated risk factors.
a total of 364 breast cancer patients were evaluated, 286 who used tamoxifen and 78 who did not use this hormone therapy. Results: patients who used tamoxifen had a mean follow-up time of 51.42 months similar to those without hormone therapy (p=0.081). A total of 21 (7.3%) women who used tamofixen and no cases among women without hormone therapy presented endometrial changes during follow-up (p=0.01). Despite information regarding obesity was available for only 270 women, obesity was also significantly associated with the development of endometrial changes (p=0.008).
furthermore, the association between tamofixen and endometrial changes remained significant (p=0.039) after adjusting for obesity.</description><subject>Breast Neoplasms</subject><subject>Breast Neoplasms - pathology</subject><subject>Endometrial Neoplasms - chemically induced</subject><subject>Endometrial Neoplasms - epidemiology</subject><subject>Female</subject><subject>Hormones</subject><subject>Humans</subject><subject>Obesity</subject><subject>Obesity - complications</subject><subject>Original</subject><subject>Retrospective Studies</subject><subject>Risk Factors</subject><subject>Tamoxifen</subject><subject>Tamoxifen - adverse effects</subject><subject>Uterine Diseases</subject><issn>0100-6991</issn><issn>1809-4546</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>DOA</sourceid><recordid>eNpVkd9uFCEUh4nR2LX6Cg0vMAoD7IA3xjT-adLExOg1OQtndqkzMAF249756NKu3dgryOH8vgN8hFxx9pYrw94xzli3NoZj17NeCCn7DuMzsuKamU4quX5OVuemC_KqlDvGpOBGvCQXohWVFmpF_nwP5RcdwdWUCx1TpnWH1OMBp7TMGCtNI8Xo04w1B5johCWkWGiIdJMRSqUOosNMF6ih9Re6LyFuaYU5_T4uO4zvKdDc0qks6Go4IHVpl3Klpe798TV5McJU8M2_9ZL8_Pzpx_XX7vbbl5vrj7edk0LFzshx40dUeuwHwwzrQbkRuNajAj0gAz94iR6E7jWAEkPv-JoLxxX20LbiktycuD7BnV1ymCEfbYJgHwopby3kGtyEVivtYTN4o5mWQjZgz_RgtPHOt0u4xvpwYi37zYzetWdnmJ5An57EsLPbdLCcKaOYlI2wPhFc-5aScTyHObP3gu29O_sg2D4Kthhb8Or_0efYo1HxF7tUpws</recordid><startdate>2023</startdate><enddate>2023</enddate><creator>Vizzotto, Jr, Alvo Orlando</creator><creator>Nicolau, Sergio Mancini</creator><creator>Lopes, Guilherme Munhoz</creator><creator>Castelo Filho, Adauto</creator><general>Colégio Brasileiro de Cirurgiões</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-6745-6502</orcidid><orcidid>https://orcid.org/0000-0002-0290-6143</orcidid><orcidid>https://orcid.org/0000-0003-3682-8443</orcidid><orcidid>https://orcid.org/0000-0003-3767-7616</orcidid></search><sort><creationdate>2023</creationdate><title>Risk factors for the development of endometrial lesions in breast cancer patients using tamoxyphen: a retrospective cohort study</title><author>Vizzotto, Jr, Alvo Orlando ; Nicolau, Sergio Mancini ; Lopes, Guilherme Munhoz ; Castelo Filho, Adauto</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c435n-94fbdfe58f2790902a5cfa188f5a87e0ad7d4eda3828aa5372c1613c15e2ac163</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Breast Neoplasms</topic><topic>Breast Neoplasms - pathology</topic><topic>Endometrial Neoplasms - chemically induced</topic><topic>Endometrial Neoplasms - epidemiology</topic><topic>Female</topic><topic>Hormones</topic><topic>Humans</topic><topic>Obesity</topic><topic>Obesity - complications</topic><topic>Original</topic><topic>Retrospective Studies</topic><topic>Risk Factors</topic><topic>Tamoxifen</topic><topic>Tamoxifen - adverse effects</topic><topic>Uterine Diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vizzotto, Jr, Alvo Orlando</creatorcontrib><creatorcontrib>Nicolau, Sergio Mancini</creatorcontrib><creatorcontrib>Lopes, Guilherme Munhoz</creatorcontrib><creatorcontrib>Castelo Filho, Adauto</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Revista do Colegio Brasileiro de Cirurgioes</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vizzotto, Jr, Alvo Orlando</au><au>Nicolau, Sergio Mancini</au><au>Lopes, Guilherme Munhoz</au><au>Castelo Filho, Adauto</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Risk factors for the development of endometrial lesions in breast cancer patients using tamoxyphen: a retrospective cohort study</atitle><jtitle>Revista do Colegio Brasileiro de Cirurgioes</jtitle><addtitle>Rev Col Bras Cir</addtitle><date>2023</date><risdate>2023</risdate><volume>50</volume><spage>e20233442</spage><pages>e20233442-</pages><issn>0100-6991</issn><eissn>1809-4546</eissn><abstract>breast cancer is the cancer with the highest incidence in women in Brazil, representing 29.7% of all cancers. More than two thirds of women with breast cancer show expression for hormone receptors, and in these cases, hormone therapy with tamoxifen is indicated, which may represent a risk factor for the development of endometrial cancer (four-fold greater relative risk).
this study aimed to evaluate the association of tamoxifen and the development of endometrial disturbances and to assess possible other associated risk factors.
a total of 364 breast cancer patients were evaluated, 286 who used tamoxifen and 78 who did not use this hormone therapy. Results: patients who used tamoxifen had a mean follow-up time of 51.42 months similar to those without hormone therapy (p=0.081). A total of 21 (7.3%) women who used tamofixen and no cases among women without hormone therapy presented endometrial changes during follow-up (p=0.01). Despite information regarding obesity was available for only 270 women, obesity was also significantly associated with the development of endometrial changes (p=0.008).
furthermore, the association between tamofixen and endometrial changes remained significant (p=0.039) after adjusting for obesity.</abstract><cop>Brazil</cop><pub>Colégio Brasileiro de Cirurgiões</pub><pmid>36995835</pmid><doi>10.1590/0100-6991e-20233442-en</doi><orcidid>https://orcid.org/0000-0001-6745-6502</orcidid><orcidid>https://orcid.org/0000-0002-0290-6143</orcidid><orcidid>https://orcid.org/0000-0003-3682-8443</orcidid><orcidid>https://orcid.org/0000-0003-3767-7616</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0100-6991 |
| ispartof | Revista do Colegio Brasileiro de Cirurgioes, 2023, Vol.50, p.e20233442 |
| issn | 0100-6991 1809-4546 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10595044 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; PubMed Central Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Breast Neoplasms Breast Neoplasms - pathology Endometrial Neoplasms - chemically induced Endometrial Neoplasms - epidemiology Female Hormones Humans Obesity Obesity - complications Original Retrospective Studies Risk Factors Tamoxifen Tamoxifen - adverse effects Uterine Diseases |
| title | Risk factors for the development of endometrial lesions in breast cancer patients using tamoxyphen: a retrospective cohort study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T11%3A26%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Risk%20factors%20for%20the%20development%20of%20endometrial%20lesions%20in%20breast%20cancer%20patients%20using%20tamoxyphen:%20a%20retrospective%20cohort%20study&rft.jtitle=Revista%20do%20Colegio%20Brasileiro%20de%20Cirurgioes&rft.au=Vizzotto,%20Jr,%20Alvo%20Orlando&rft.date=2023&rft.volume=50&rft.spage=e20233442&rft.pages=e20233442-&rft.issn=0100-6991&rft.eissn=1809-4546&rft_id=info:doi/10.1590/0100-6991e-20233442-en&rft_dat=%3Cpubmed_doaj_%3E36995835%3C/pubmed_doaj_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/36995835&rft_doaj_id=oai_doaj_org_article_858dab7d980843428a2087989dcdbdfc&rfr_iscdi=true |